Sanofi Anticipates the Approval of its COVID-19 Vaccine by First Half of 2021

Sanofi Anticipates the Approval of its COVID-19 Vaccine by First Half of 2021

Shots:

  • Sanofi divulges in its virtual R&D day that the company is anticipating initiation of P-I/II study evaluating the recombinant protein-based​ vaccine candidate (baculovirus), developing in collaboration with GSK while expecting the complete approval in H1’20
  • Sanofi also highlights capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients
  • Additionally, Sanofi reveals the clinical status of Venglustat for which P-II/III clinical trial in Gaucher disease type 3 is ongoing, P-III study in Tay-Sachs disease, a type of GM-2 gangliosidoses, was initiated at the beginning of 2020 while P-III study in Fabry diseases to be initiated in 2021

Click here to read full press release/ article | Ref: Sanofi | Image: Pharmaceutical Technology

Related News: Sanofi and GSK Collaborate to Develop Adjuvanted COVID-19 Vaccine

Sanofi’s COVID-19 Vaccine to be Available Globally